NATCO Pharma Limited

NSE NATCOPHARM.NS

NATCO Pharma Limited Current Liabilities for the year ending March 31, 2024: USD 116.63 M

NATCO Pharma Limited Current Liabilities is USD 116.63 M for the year ending March 31, 2024, a 40.33% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

NATCO Pharma Limited Current Liabilities for the year ending March 31, 2023 was USD 83.11 M, a -11.17% change year over year.
NATCO Pharma Limited Current Liabilities for the year ending March 31, 2022 was USD 93.56 M, a 30.34% change year over year.
NATCO Pharma Limited Current Liabilities for the year ending March 31, 2021 was USD 71.78 M, a -21.07% change year over year.
NATCO Pharma Limited Current Liabilities for the year ending March 31, 2020 was USD 90.94 M, a -13.28% change year over year.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

NSE: NATCOPHARM.NS

NATCO Pharma Limited

CEO	Mr. Rajeev Nannapaneni
IPO Date	Jan. 1, 1996
Location	India
Headquarters	NATCO House
Employees	4,016
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies

Description

NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina and CHF. The company markets its products in approximately 40 countries, including India, the United States, and internationally. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Key trends

Past 5 years